Ambu Valuation

Q: What is the Fair Price of 0MJF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0MJF (DKK137.6) is trading above our estimate of [[fair value]] (DKK132.14)

Is 0MJF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MJF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

DKK 132.14

Fair Value

4.1% overvalued

Number of Analysts

Below Fair Value: 0MJF (DKK137.6) is trading above our estimate of fair value (DKK132.14)

Significantly Below Fair Value: 0MJF is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MJF?

Key metric: As 0MJF is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0MJF. This is calculated by dividing 0MJF's market cap by their current revenue.
What is 0MJF's PS Ratio?
PS Ratio	6.8x
Sales	DKK 0
Market Cap	DKK 37.13b

0MJF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.9x
Enterprise Value/EBITDA	46.2x
PEG Ratio	97.7x

Price to Sales Ratio vs Peers

How does 0MJF's PS Ratio compare to its peers?

The above table shows the PS ratio for 0MJF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.3x
SN. Smith & Nephew	2x	4.8%	UK£8.9b
NIOX NIOX Group	6.1x	11.6%	UK£238.8m
CREO Creo Medical Group	2.4x	1.3%	UK£72.4m
CTEC ConvaTec Group	2.9x	5.6%	UK£5.1b
0MJF Ambu	6.8x	1.7%	DKK 37.1b

Price-To-Sales vs Peers: 0MJF is expensive based on its Price-To-Sales Ratio (6.8x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does 0MJF's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
SPEC INSPECS Group	0.2x	5.3%	US$50.00m
YGEN Yourgene Health	0.6x	n/a	US$20.48m
IHC Inspiration Healthcare Group	0.3x	13.6%	US$14.34m
SUN Surgical Innovations Group	0.4x	n/a	US$6.10m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0MJF is expensive based on its Price-To-Sales Ratio (6.8x) compared to the UK Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 0MJF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MJF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.8x
Fair PS Ratio	2.4x

Price-To-Sales vs Fair Ratio: 0MJF is expensive based on its Price-To-Sales Ratio (6.8x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MJF forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 136.25	DKK 139.15 +2.1%	19.7%	DKK 165.00	DKK 76.00	n/a	8
Jan ’26	DKK 104.76	DKK 127.70 +21.9%	18.5%	DKK 160.00	DKK 76.00	n/a	7
Dec ’25	DKK 111.13	DKK 127.63 +14.8%	18.5%	DKK 160.00	DKK 76.00	n/a	7
Nov ’25	DKK 128.04	DKK 128.67 +0.5%	18.5%	DKK 145.00	DKK 76.00	n/a	6
Oct ’25	DKK 131.20	DKK 125.50 -4.3%	19.1%	DKK 145.00	DKK 76.00	n/a	6
Sep ’25	DKK 130.11	DKK 126.40 -2.8%	21.9%	DKK 160.00	DKK 76.00	n/a	5
Aug ’25	DKK 139.85	DKK 117.00 -16.3%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jul ’25	DKK 136.69	DKK 117.00 -14.4%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jun ’25	DKK 131.69	DKK 111.20 -15.6%	24.9%	DKK 138.00	DKK 59.00	n/a	5
May ’25	DKK 111.75	DKK 107.20 -4.1%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Apr ’25	DKK 111.94	DKK 107.20 -4.2%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Mar ’25	DKK 121.05	DKK 107.20 -11.4%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Feb ’25	DKK 113.40	DKK 105.00 -7.4%	26.7%	DKK 130.00	DKK 52.00	n/a	5
Jan ’25	DKK 105.30	DKK 85.67 -18.6%	26.2%	DKK 115.00	DKK 47.00	DKK 104.76	6
Dec ’24	DKK 92.25	DKK 85.67 -7.1%	26.2%	DKK 115.00	DKK 47.00	DKK 111.13	6
Nov ’24	DKK 69.71	DKK 89.40 +28.2%	28.2%	DKK 120.00	DKK 53.00	DKK 128.04	5
Oct ’24	DKK 73.93	DKK 95.60 +29.3%	25.6%	DKK 120.00	DKK 53.00	DKK 131.20	5
Sep ’24	DKK 83.45	DKK 96.00 +15.0%	25.3%	DKK 120.00	DKK 53.00	DKK 130.11	5
Aug ’24	DKK 99.48	DKK 101.80 +2.3%	27.0%	DKK 135.00	DKK 59.00	DKK 139.85	5
Jul ’24	DKK 110.22	DKK 102.60 -6.9%	26.9%	DKK 135.00	DKK 59.00	DKK 136.69	5
Jun ’24	DKK 108.68	DKK 102.60 -5.6%	26.9%	DKK 135.00	DKK 59.00	DKK 131.69	5
May ’24	DKK 107.66	DKK 101.60 -5.6%	28.4%	DKK 135.00	DKK 55.00	DKK 111.75	5
Apr ’24	DKK 102.49	DKK 96.25 -6.1%	30.8%	DKK 135.00	DKK 55.00	DKK 111.94	4
Mar ’24	DKK 103.47	DKK 104.60 +1.1%	30.2%	DKK 140.00	DKK 55.00	DKK 121.05	5
Feb ’24	DKK 99.64	DKK 87.80 -11.9%	20.6%	DKK 110.00	DKK 65.00	DKK 113.40	5
Jan ’24	DKK 90.31	DKK 83.40 -7.7%	19.5%	DKK 110.00	DKK 65.00	DKK 105.30	5

Analyst Price Target

Consensus Narrative from 8 Analysts

DKK 139.15

Fair Value

1.1% undervalued

Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/30 15:06
End of Day Share Price	2025/01/30 00:00
Earnings	2024/12/31
Annual Earnings	2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ambu A/S is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Michael Healy	Berenberg
Alexander Berglund	BofA Global Research